MedTrace Logo

Immune Checkpoint Inhibitors (ICIs) Retreatment in Second-line Treatment of Advanced Gastric Cancer: a Retrospective, Real-world Study

NCT06814548 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2025-02-07

No results posted yet for this study

Summary

This is a single-center, retrospective, observational, real-world study. We collected general and clinical data of patients with advanced gastric cancer who were admitted to the First Affiliated Hospital of Zhengzhou University from January 2018 to July 2024.

Conditions

  • Gastric Cancer, Gastroesophageal Junction Cancer
  • Immune Checkpoint Inhibitors (ICIs)
  • Second-line
  • Retreatment

Interventions

OTHER

ICIs(Immune checkpoint inhibitors)

N

Sponsors & Collaborators

  • Yongxu Jia

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-10
Primary Completion
2025-05-31
Completion
2025-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06814548 on ClinicalTrials.gov